Roche’s Obesity Drug Boosts Blood Sugar Control, Drives 15.5% Weight Loss in Mid-Stage Trial

Roche’s obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial

Sept 22 (Reuters) - Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood ​sugar levels and lose an average 15.5% ‌of their body weight in a mid-stage trial...

Roche obesity shot cuts body weight 15.5% in mid-stage trial

The global market for weight-loss drugs is estimated to reach as much as $150 billion.

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep 22, 2026-

Roche’s obesity drug boosts blood sugar control, drives 15.5 percent weight loss in mid-stage trial

GENEVA (Reuters) : Swiss drugmaker Roche ‌said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5 percent of their body weight in a mid-stage trial. Roche is racing alongside large drugmakers, including AstraZeneca and Amgen, to break into the […]